Biomarker Discovery and Development
Biomarker Discovery and Development
Unlocking high-resolution biomarkers from RNA
ATLUS Targeting enables a new approach to biomarker discovery by capturing the full complexity of RNA isoforms directly from patient samples, including both tissue and blood.
By combining targeted enrichment with full-length sequencing, it reveals clinically relevant signals, such as splice variants and fusion-driven isoforms, that are often missed by conventional methods.
What it enables
High-Resolution Biomarker Discovery
Identification of novel, disease-relevant RNA isoforms with high sensitivity.
Functional Insight
Precise characterisation of transcript variants that influence protein function, disease progression, and therapeutic response.
Contextual Validation
Evaluation of biomarkers within transcriptome-wide expression patterns to improve biological and clinical relevance.
Why it matters
More precise biomarkers lead to better decisions.
ATLUS supports the development of predictive biomarkers for patient stratification, therapy selection, and resistance monitoring, accelerating both drug development and diagnostic innovation.
